Mark M. Moasser, MD

University of Pennsylvania, Philadelphia, PA, B.A., 1984
Tufts University School of Medicine, Boston, MA, M.D., 1988
The New York Hospital - Cornell Medical Center, New York, NY, 1988-1991, Internal Medicine (Residency)
Memorial Sloan-Kettering Cancer Center, New York, NY, 1991-1996, Medical Oncology (Fellowship)

• 1996-1999
  Instructor, Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Dept of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
• 1999-2004
  Clinical Assistant, Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Dept Of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2004-2007
  Associate Clinical Professor, Department of Medicine and Cancer Center, Breast Cancer Program, University of California, San Francisco
• 2008-2010
  Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco
• 2010-present
  Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

• 1984
  Phi Beta Kappa
• 1992-1993
  Clinical and Molecular Cancer Research Training Fellowship Award
• 1994
  American Society for Clinical Oncology Young Investigator Award (declined)
• 1993-1995
  Charles A. Dana Fellowship Award
• 1993-1995
  Clinical Scholars Award, Biomedical Research Training Program, Sloan-Kettering Institute
• 1995-1996
  Ethel Abbott Fellowship Award
• 1997-1999
  Byrne Fund Award
• 1997-2000
  American Society for Clinical Oncology Career Development Award
• 2002-2006
  American Cancer Society Research Scholar
• 2005-2007
  Susan Komen Breast Cancer Research Foundation Award
• 2005-2006
  California Breast Cancer Research Program Award
• 2008
  Elected to the American Society for Clinical Investigation

• Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1369-74. PubMed PMID: 9465021; PubMed Central PMCID: PMC19006.
• Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59(24):6145-52. PubMed PMID: 10626805.
• Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8. PubMed PMID: 11585753.
• Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr;9(4):1267-73. PubMed PMID: 12684394.
• She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 1;9(12):4340-6. PubMed PMID: 14555504.
• Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004 Jun;3(6):796-803. Epub 2004 Jun 5. PubMed PMID: 15136770.
• Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11;24(34):5333-43. PubMed PMID: 16007225; PubMed Central PMCID: PMC3023961.
• Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7. PubMed PMID: 17206155; PubMed Central PMCID: PMC3025857.
• Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review. PubMed PMID: 17667926; PubMed Central PMCID: PMC2360352.
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007 Oct 4;26(45):6469-87. Epub 2007 Apr 30. Review. PubMed PMID: 17471238; PubMed Central PMCID: PMC3021475.
• Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007 Oct 11;26(46):6577-92. Epub 2007 May 7. Review. PubMed PMID: 17486079.
• Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec;13(12):527-34. Epub 2007 Nov 5. Review. PubMed PMID: 17981505; PubMed Central PMCID: PMC3035105.
• Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec;26(6):1618-25. PubMed PMID: 17968965; PubMed Central PMCID: PMC3024590.
• Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39. Review. PubMed PMID: 18410794.
• Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008 May;65(10):1566-84. Review. PubMed PMID: 18259690; PubMed Central PMCID: PMC3060045.
• Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 1;415(1):97-110. PubMed PMID: 18498248.
• Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Review. PubMed PMID: 19037833; PubMed Central PMCID: PMC3031872.
• Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 1;15(7):2311-22. Epub 2009 Mar 24. PubMed PMID: 19318475; PubMed Central PMCID: PMC3023342.
• Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May;174(5):1756-65. Epub 2009 Apr 6. PubMed PMID: 19349359; PubMed Central PMCID: PMC2671264.
• Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May;29(5):1071-9. PubMed PMID: 19388114.
• Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1;15(17):5569-75. Epub 2009 Aug 25. PubMed PMID: 19706807; PubMed Central PMCID: PMC3029022.
• Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27;2(16):16ra7. PubMed PMID: 20371474; PubMed Central PMCID: PMC3033659
• Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 1;16(5):1373-83. Epub 2010 Feb 23. PubMed PMID: 20179223; PubMed Central PMCID: PMC2831167.
• Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec;21(9):944-50. Epub 2010 Sep 9. Review. PubMed PMID: 20816829; PubMed Central PMCID: PMC2991618.
• Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb;31(4):766-82. Epub 2010 Dec 28. PubMed PMID: 21189288; PubMed Central PMCID: PMC3028653.
• Spassov DS, Wong CH, Ahuja D, Moasser MM. The structural features of Trask that mediate its anti-adhesive function. PLoS One 2011 (in press)
• Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle 2001; (in press)